Nevada Candidate Carrie Buck Faces Criticism Over Prescription Drug Pricing Stance
Carrie Buck, a Republican figure in the Nevada political scene, is under scrutiny as she campaigns for a Congressional seat in Nevada’s 1st District. Despite her platform emphasizing cost reduction, Buck has faced backlash for her past opposition to measures aimed at decreasing prescription drug prices.
The 1st District, encompassing parts of Las Vegas and Henderson, could soon be represented by Buck, who has served in the Nevada Senate since 2020. Her campaign’s emphasis on economic issues contrasts with her legislative history, notably her stance against Assembly Bill 250 in 2023.
Assembly Bill 250 aimed to broaden the reach of Medicare drug savings to benefit all residents of Nevada. The bill, designed to apply federal price negotiations to medications such as those for diabetes, heart failure, and autoimmune diseases, was a focal point for healthcare affordability. Former Lt. Gov. Kate Marshall ardently supported the bill, expressing that such measures are essential for public welfare.
“People have the right to have access to medication at a reasonable price,” Marshall remarked to the Nevada Independent. Stressing the ongoing economic hardships, she added, “We are obligated as public servants to extend a hand and say, ‘I am there with you.’”
Buck, defending her stance, expressed concerns about the broader implications of price capping. “Anytime you put caps on things, I really worry about the greater impact,” she stated in 2024, without further detailing her objections. The bill, although passed by the Nevada Legislature, was ultimately vetoed by Republican Governor Joe Lombardo. Democrats have expressed intentions to reintroduce the legislation.
Moreover, Buck voiced opposition to the 2021 Inflation Reduction Act, a federal initiative that facilitated negotiations for reduced drug prices, benefiting over 140,000 Nevadans. Buck described the act as a “disaster,” contrasting the support it received from her political rival, Democratic Rep. Dina Titus. Titus lauded the act’s potential to alleviate healthcare and energy costs for families.
“This historic legislation will make a difference for families by lowering health care costs, cutting prescription drug prices, and reducing the price of energy,” Titus asserted in a statement made following the act’s passage.
Despite the controversy, Buck’s campaign has received an endorsement from former President Donald Trump, indicating substantial support within her party.
